Human Papillomavirus-Associated Anal Cancer Incidence and Burden Among US Men, According to Sexual Orientation, Human Immunodeficiency Virus Status, and Age
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciad205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Ashish A Deshmukh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health Sciences, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA. Hauptthemen laut MEDLINE: HIV Infections, Anus Diseases, Papillomavirus Infections, Sexual and Gender Minorities. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: World Health Organization, NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Background
Men who have sex with men (MSM) without HIV are known to be at elevated relative risk for Human papillomavirus (HPV)-associated anal cancer in comparison to men who have sex with women (MSW), but are poorly characterized in terms of anal cancer incidence due to absence of reporting of sexual behavior/identity at a population-level.
Methods
By combining age-specific statistics from multiple data sources (anal cancer incidence among all males; anal cancer incidence among MSM and MSW with HIV; population size of men with HIV by sexual orientation), we developed a mathematical model to estimate anal cancer incidence, annual number of cases, and proportion by (a) sexual orientation (MSM versus MSW), (b) HIV status, and (c) age (<30, 30–44, 45–59, and ≥60 years).
Results
Anal cancer incidence (per 100 000) among MSM without HIV was 1.4 (95% uncertainty interval [UI], 0.6 to 2.3), 17.6 (95% UI = 13.8–23.5), and 33.9 (95% UI = 28.3–42.3), at ages 30–44, 45–59 and ≥60 years, respectively. 19.1% of all male anal cancer occurred in MSM without HIV, increasing from 4% of anal cancer diagnosed at 30–44 years to 24% at ≥60 years; 54.3% occurred in MSW without HIV (increasing from 13% at age 30–44 to 67% at >60 years), and the remaining 26.6% in men (MSM and MSW combined) with HIV (decreasing from 83% at age 30–44 to 9% at >60 years).
Conclusions
These findings should inform anal cancer prevention recommendations in male risk groups, including, for the first time, for the important group of MSM without HIV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Public Health Sciences, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA.
- Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
ORCID-Profile: Kalyani Sonawane
Förderung
- World Health Organization
- NCI NIH HHS
- National Cancer Institute
- National Institute on Minority Health and Health Disparities
Zitieren
APA
Deshmukh, A. A., Damgacioglu, H., Georges, D., Sonawane, K., & Clifford, G. M. (2023). Human Papillomavirus-Associated Anal Cancer Incidence and Burden Among US Men, According to Sexual Orientation, Human Immunodeficiency Virus Status, and Age. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad205
Vancouver
Deshmukh AA, Damgacioglu H, Georges D, Sonawane K, Clifford GM. Human Papillomavirus-Associated Anal Cancer Incidence and Burden Among US Men, According to Sexual Orientation, Human Immunodeficiency Virus Status, and Age. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad205
BibTeX
@article{Deshmukh2023,
author = {Deshmukh, Ashish A and Damgacioglu, Haluk and Georges, Damien and Sonawane, Kalyani and Clifford, Gary M},
title = {Human Papillomavirus-Associated Anal Cancer Incidence and Burden Among US Men, According to Sexual Orientation, Human Immunodeficiency Virus Status, and Age},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciad205}
}
EUVIMED